Investor Presentaiton
Revenue
Increased by 16.2 Bn JPY (Decreased by 1.1 Bn JPY excl. forex impact)
Daiichi-Sankyo
Positive Factors
(Bn JPY)
Negative Factors
FY2021 Q1 Results
Japan Business
(incl. Innovative Pharmaceuticals,
Generic, Vaccines, OTC)
Oncology Business*1
American Regent
EU Specialty Business
264.1
Japan Business Unit
Lixiana
18.1
Tarlige
+2.2
+1.8
Nexium
-19.7
8.8
Daiichi Sankyo Espha
+1.0
Vaccines business
-0.9
0.7
|
Oncology Business*1 Unit
Enhertu
+11.8
Olmesartan
-1.5
2.8
ASCA
American Regent Unit
1.6
(Asia, South and Central America)
Venofer
+2.5
Injectafer
-2.9
Enhertu, Dato-DXd*2
GE injectables
+1.0
3.1
Upfront Payment &
Regulatory Milestone
EU Specialty Business Unit
Lixiana
+3.9
Forex Impact*3
17.3
Gain on sales of transferring
long-listed products
-1.1
FY2022 Q1 Results
280.3
Positive Factors
Negative Factors
*1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products
*2 Dato-DXd: Datopotamab deruxtecan (DS-1062)
*3 Forex impact USD: +11.5, EUR: +1.9, ASCA: +3.8
Enhertu, Dato-DXd*² Upfront Payment & Regulatory Milestone
Enhertu Regulatory Milestone +2.8
5View entire presentation